2/6/2012

The FDA removed a partial clinical hold on Idenix Pharmaceuticals' nucleotide polymerase inhibitor IDX184.
The oral treatment, which is undergoing a midstage trial, has demonstrated activity against genotype 1 hepatitis C without causing serious adverse effects,
the company reported.

Related Summaries